Slough's new chief executive, Ian Coull, has asked UBS to draw up a range of options for unlocking the value in its American assets. These include a sale, wholesale demerger, retaining a stake in a new company or a tax-efficient property investment trust.
The aim is to streamline Slough into a specialist development company better equipped to generate improved returns on capital than it can from pure property investment.
Slough has built a profitable business in the southern California property market with the development of the biotechnology parks. They have attracted tenants like Pfizer which now occupies 25% of the property in the portfolio and this has boosted the investment value of the estate.
Continue Reading for Free
Register and gain access to:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
